Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells.
PURPOSE: This phase II trial is studying how well radiolabeled monoclonal antibody works in treating patients with progressive metastatic androgen-independent adenocarcinoma (cancer) of the prostate.
Full description
OBJECTIVES:
Primary
Secondary
OUTLINE: This is a multicenter, open-label study.
Patients receive a single dose of lutetium Lu 177 monoclonal antibody J591 IV on day 1. Patients then undergo radionuclide scanning between days 6-8 to confirm tumor targeting by the study drug.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 17-32 patients will be accrued for this study.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
DISEASE CHARACTERISTICS:
Histologically confirmed adenocarcinoma of the prostate
Progressive disease after prior antiandrogen therapy, as evidenced by at least 1 of the following parameters:
New osseous lesions on bone scan
Greater than 25% increase in the sum of the products of the longest perpendicular diameters of the lesions OR the appearance of new lesions on MRI or CT scan
Rising prostate-specific antigen (PSA) despite adequate medical or surgical castration therapy
Measurable or evaluable disease
Serum testosterone ≤ 50 ng/dL
No confluent lesions involving axial and appendicular skeleton on bone scan ("superscan")
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Pulmonary
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
See Disease Characteristics
Concurrent luteinizing hormone-releasing hormone (LHRH) analog allowed provided 1 of the following is true:
More than 4 weeks since prior corticosteroids
More than 4 weeks since prior adrenal hormone inhibitors
Concurrent low-dose prednisone (≤ 5mg/day) for adrenal insufficiency allowed
No concurrent finasteride
Radiotherapy
Surgery
Other
More than 4 weeks since prior PC-SPES
More than 4 weeks since prior investigational therapy (medications or devices)
At least 1 week since prior aspirin and/or nonsteroidal anti-inflammatory agents possessing antiplatelet activity
At least 1 week since prior antiplatelet medication, including the following:
No concurrent anticoagulant medications (for platelet count < 50,000/mm^3), including the following:
No other concurrent investigational therapy
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal